Daijiro Harada1, Kenji Takata2, Shunta Mori3, Toshiyuki Kozuki3, Yoshika Takechi4, Satoko Moriki4, Yumi Asakura4, Takayuki Ohno4, Naoyuki Nogami3. 1. Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan h401068@yahoo.co.jp. 2. Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan. 3. Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. 4. Department of Pharmacy, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Abstract
BACKGROUND/AIM: For immune checkpoint inhibitor (ICI)-pretreated patients, docetaxel and ramucirumab (DOC+RAM) combination therapy may be more effective compared to patients not receiving ICI treatment. PATIENTS AND METHODS: From June 2013 to July 2018, 39 patients with advanced/recurrent non-small cell lung cancer underwent DOC+RAM therapy. We analyzed the efficacy and safety of DOC+RAM therapy based on the presence (pre-ICI+) or absence (pre-ICI-) of ICI pretreatment history. RESULTS: Of the 39 patients treated with DOC+RAM, we identified 18 (46%) pre-ICI+ patients. Overall response rates for DOC+RAM concerning pre-ICI+ and pre-ICI- patients were 38.9% vs. 19.0%, respectively. Median progression-free survival (PFS) was 5.7 vs. 2.3 months [hazard ratio(HR)=0.36; 95% confidence interval (CI)=0.16-0.80]. Adverse events such as fever, myalgia, arthritis, pleural effusion, and pneumonitis tended to be increased in pre-ICI+ patients. CONCLUSION: Despite increased toxicity concerns, DOC+RAM therapy in pre-ICI+ patients showed a trend for tumor regression improvement and statistically significant prolongation of PFS. Copyright
BACKGROUND/AIM: For immune checkpoint inhibitor (ICI)-pretreated patients, docetaxel and ramucirumab (DOC+RAM) combination therapy may be more effective compared to patients not receiving ICI treatment. PATIENTS AND METHODS: From June 2013 to July 2018, 39 patients with advanced/recurrent non-small cell lung cancer underwent DOC+RAM therapy. We analyzed the efficacy and safety of DOC+RAM therapy based on the presence (pre-ICI+) or absence (pre-ICI-) of ICI pretreatment history. RESULTS: Of the 39 patients treated with DOC+RAM, we identified 18 (46%) pre-ICI+ patients. Overall response rates for DOC+RAM concerning pre-ICI+ and pre-ICI- patients were 38.9% vs. 19.0%, respectively. Median progression-free survival (PFS) was 5.7 vs. 2.3 months [hazard ratio(HR)=0.36; 95% confidence interval (CI)=0.16-0.80]. Adverse events such as fever, myalgia, arthritis, pleural effusion, and pneumonitis tended to be increased in pre-ICI+ patients. CONCLUSION: Despite increased toxicity concerns, DOC+RAM therapy in pre-ICI+ patients showed a trend for tumor regression improvement and statistically significant prolongation of PFS. Copyright
Authors: Wolfgang M Brueckl; Martin Reck; Achim Rittmeyer; Jens Kollmeier; Claas Wesseler; Gunther H Wiest; Petros Christopoulos; Amanda Tufman; Petra Hoffknecht; Bernhard Ulm; Fabian Reich; Joachim H Ficker; Eckart Laack Journal: Clin Med Insights Oncol Date: 2020-08-19
Authors: Reid W Merryman; Robert A Redd; Taiga Nishihori; Julio Chavez; Yago Nieto; Justin M Darrah; Uttam Rao; Michael T Byrne; David A Bond; Kami J Maddocks; Michael A Spinner; Ranjana H Advani; Hatcher J Ballard; Jakub Svoboda; Anurag K Singh; Joseph P McGuirk; Dipenkumar Modi; Radhakrishnan Ramchandren; Jason Romancik; Jonathon B Cohen; Matthew J Frigault; Yi-Bin Chen; Anthony V Serritella; Justine Kline; Stephen Ansell; Sunita Nathan; Maryam Rahimian; Robin M Joyce; Mansi Shah; Kevin A David; Steven Park; Anne W Beaven; Alma Habib; Veronika Bachanova; Shazia Nakhoda; Nadia Khan; Ryan C Lynch; Stephen D Smith; Vincent T Ho; Ann LaCasce; Philippe Armand; Alex F Herrera Journal: Blood Adv Date: 2021-03-23
Authors: Wolfgang M Brueckl; Martin Reck; Achim Rittmeyer; Jens Kollmeier; Claas Wesseler; Gunther H Wiest; Petros Christopoulos; Albrecht Stenzinger; Amanda Tufman; Petra Hoffknecht; Bernhard Ulm; Fabian Reich; Joachim H Ficker; Eckart Laack Journal: Transl Lung Cancer Res Date: 2021-07